Clinical Trials Logo

Filter by:
  • Enrolling by invitation  
  • Page [1] ·  Next »
NCT ID: NCT03294265 Enrolling by invitation - Clinical trials for Type 2 Diabetes Mellitus

A Peer Support Program to Enhance Treatment Adherence in Patients With Type 2 DM

Start date: August 1, 2016
Phase: N/A
Study type: Interventional

Diabetes Mellitus (DM) affects patients' quality of life in different dimensions. Therefore, it is considered a priority to design and create specialized intervention programs in order to prevent and decrease complications. The peer support program studies have shown to Increase adherence to treatment and the proportion of patients with adequate long-term metabolic control. The benefits that these programs bring are the social and emotional support in the daily management of the disease through shared experiences and communication in a continuous way. There are only a few peer support programs in Mexico, thus it is required to investigate the effects of their implementation in our environment to promote empowerment and maintain long-term lifestyle changes. The present study has the objective to enhance self-care behaviors and health empowerment in patients with diabetes through peer support.

NCT ID: NCT03047395 Enrolling by invitation - Psoriasis Clinical Trials

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis

Start date: February 27, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.

NCT ID: NCT02946411 Enrolling by invitation - Clinical trials for Stress Hyperglycemia

Correlation of Hospital Stay Length With the Glucose Levels After Cardiac Surgery

Start date: November 1, 2016
Phase: N/A
Study type: Observational

The study is designed to test if there is any correlation between the glucose levels in the postoperatory period and the length of hospital stay.

NCT ID: NCT02892422 Enrolling by invitation - Schizophrenia Clinical Trials

Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia

Debut
Start date: August 2016
Phase: Phase 3
Study type: Interventional

To evaluate the safety and tolerability of the long-term treatment with Lu AF35700.

NCT ID: NCT02871297 Enrolling by invitation - Clinical trials for Depressive Disorder, Major

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Start date: August 2016
Phase: Phase 3
Study type: Interventional

Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent patients with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD

NCT ID: NCT02773355 Enrolling by invitation - Obesity Clinical Trials

Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

Start date: May 16, 2016
Phase: N/A
Study type: Observational

This trial is conducted in North America. The aim is to investigate timely detection of pancreatitis cases as well as cases of suspicion of serious and non-serious adverse reactions possibly or probably related to Saxenda® in Mexican patients.

NCT ID: NCT02683317 Enrolling by invitation - Clinical trials for Retinopathy of Prematurity

Enteral Administration of Docosahexaenoic Acid to Prevent Retinopathy of Prematurity

Start date: February 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether docosahexaenoic acid given by enteral feeding prevent retinopathy of prematurity and/or diminish its severity in preterm infants.

NCT ID: NCT02570737 Enrolling by invitation - Clinical trials for Pulmonary Hypertension

Latin American Pulmonary Hypertension Registry

RELAHP
Start date: April 2014
Phase: N/A
Study type: Observational [Patient Registry]

The RELAHP registry is a Latin-American multinational, multicenter, prospective observational registry-type cohort study, which pretends to identify clinical characteristics, clinical course, management and outcome of all forms of pulmonary hypertension (PH). All consecutively consented patients newly diagnosed with WHO Group I-V PH according to specific hemodynamic criteria on right heart catheterization at the participating centers will be enrolled. Patients will be followed six-monthly for a minimum of five years from the time of enrollment.

NCT ID: NCT02510261 Enrolling by invitation - Amyloidosis Clinical Trials

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Start date: July 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).

NCT ID: NCT02412787 Enrolling by invitation - Hunter Syndrome Clinical Trials

Long-Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Patients With Hunter Syndrome That Have Completed Study HGT-HIT-094

Start date: April 2015
Phase: Phase 2/Phase 3
Study type: Interventional

This extension study will allow participants that completed Study HGT-HIT-094 to continue receiving Elaprase treatment in conjunction with idursulfase IT or to continue receiving Elaprase treatment and begin concurrent IT treatment for those that did not received idursulfase IT treatment in Study HGT-HIT-094.